Skip to main content

Dermatology

Best Rheumatologists (7.19.2024)

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Read Article

Updated EULAR Recommendations on the Treatment of Systemic Sclerosis

Medscape

Medscape has published an overview to the 2024 updated recommendations for the treatment of systemic sclerosis (SSc) presented in Vienna at EULAR 2024 by Professor Francesco Del Galdo, MD, PhD on behalf of a 27 member task force.

The new recommendations (n=20)

Read Article

Systemic sclerosis sine scleroderma

Systemic sclerosis sine scleroderma (ssSSc), which accounts for nearly 10% of systemic sclerosis (SSc) patients and was first described in 1962, is a subset of SSc.

Read Article

ICYMI: 2023 EULAR Psoriatic Arthritis Recommendations

EULAR has updated its treatment recommendations from the prior 2019 guidelines, since there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.

Read Article

ICYMI: Hidradenitis Suppurativa-Related Autoinflammatory Syndromes

Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma

Read Article

ICYMI: JAMA: SLE Review

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

Read Article
Difficult-to-Treat Psoriasis This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics. https://t.co/OWzmYShqBs https://t.co/u1995MAB15
Dr. John Cush @RheumNow( View Tweet )
Vilobelimab, an anticomplement factor 5a (C5a) antibody, shown in this case report to be effective in (difficult to treat) pyoderma gangrenosum. https://t.co/P241Knoco6 https://t.co/hrCxOv8SEA
Dr. John Cush @RheumNow( View Tweet )
Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria. https://t.co/DQJ5AcwchL https://t.co/lHtCt720D9
Dr. John Cush @RheumNow( View Tweet )

Difficult-to-Treat Psoriasis

This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.

Read Article

New indications for JAK inhibitors

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article

EULAR 2024 Rheumatology Roundup (6.21.2024)

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article

New Treatments for Systemic Sclerosis

EurekAlert!

Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed. Two abstracts

Read Article

EULAR 2024 - Day 1 Report

Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article

Can we prevent psoriatic arthritis?

Psoriatic arthritis (PsA) can affect up to 30% of patients with psoriasis (PsO). Understanding the factors that predispose patients with PsO who progress to PsA is the first step in understanding how early interventions in PsO may augment the progression to PsA. At #EULAR2024, there are a few

Read Article
Full read review on Psoriasis Flares; risks: - mechanical stress - infections -dysbiosis -drugs (Lithium, B-blockers, HCQ, tetracyclines, ACEi, IFN) - environment(smoking, obesity) -lifestyle - stress - hormonal/metabolic https://t.co/WfCzcG9XNM https://t.co/ZNeKxjtHSA https://t.co/sJDoSfFOL4
Dr. John Cush @RheumNow( View Tweet )

Is Cannabis Safe? (6.7.2024)

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

Read Article

ACR’s Run at Goliath (PCPs) (5.31.2024)

Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?

Read Article

Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis

A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO. 

Read Article

The Window of Opportunity (5.24.2024)

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Read Article

Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis

A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.

Read Article

"Don't You Know Who I am?" (5.17.2024)

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Read Article

Interferons and Lupus Subsets

EurekAlert!

In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to the relationship between interferons and lupus, which affects up to 1.5 million Americans

Read Article

Cutoffs for Systemic Juvenile Arthritis Disease Activity Score

An international cohort of children with systemic Juvenile idiopathic arthritis (Still's disease) validated the systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS10), a disease activity measure distinguish patients with inactive disease, minimal disease activity, moderate disease

Read Article

Methotrexate Does Not Increase ILD Risk in Dermatomyositis

A cohort analysis of dermatomyositis (DM) patients starting immunomodulators finds that methotrexate use was not associated with an increased risk of interstitial lung disease (ILD).

ILD affects ~23% of DM patients and the oft used MTX is has a low risk of pneumonitis and pulmonary

Read Article